GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ORGANOGENESIS HOLDINGS INC. (NASDAQ: ORGO)
Grabar Law Office is investigating potential claims on behalf of Organogenesis Holdings Inc. (NASDAQ: ORGO) shareholders. The investigation concerns whether certain officers of Organogenesis have breached their fiduciary duties owed to the company.
Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets in the United States. Organogenesis’ products include, among others, “Affinity” and “PuraPly XT.”
The underlying class action lawsuit alleges that, the Company, through certain of its officers, made false and misleading statements and failed to disclose that: (i) Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by, among other things, setting the price for those products multiple times higher than similar products; (ii) Organogenesis improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements; (iii) as a result, Organogenesis’ revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and (iv) thus, Organogenesis’ public statements were materially false and misleading at all relevant times.
Current Organogenesis shareholders who have held Organogenesis stock since before March 17, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to contact us at email@example.com, or call Joshua Grabar at 267-507-6085.